Products
Obrixtamig Biosimilar Bispecific Antibody (DLL3 × CD3) for Research
Cat No.: GMP-Bios-INN-1307
Anti-DLL3 therapeutic antibody (Pre-made Obrixtamig biosimilar,Bispecific mAb (L-kappa-H-gamma1_L-lambda-H-gamma1)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Obrixtamig (development code BI-764532) is a bispecific antibody targeting DLL3. It is developed by Boehringer Ingelheim for neuroendocrine tumors and small cell lung cancer. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1307-1mg | 1mg | |
| GMP-Bios-INN-1307-10mg | 10mg | |
| GMP-Bios-INN-1307-100mg | 100mg | |
| GMP-Bios-INN-1307-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Obrixtamig biosimilar, Bispecific mAb (L-kappa-H-gamma1_L-lambda-H-gamma1), Anti-DLL3;CD3E Antibody: Anti-DLL3/Delta-like protein 3/Drosophila Delta homolog 3 (Delta3)/SCDO1 therapeutic antibody |
| INN Name | Obrixtamig |
| Target | DLL3;CD3E |
| Format | Bispecific mAb (L-kappa-H-gamma1_L-lambda-H-gamma1) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Boehringer Ingelheim |
| Conditions Approved | na |
| Conditions Active | Neuroendocrine tumours;Small cell lung cancer;Glioma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
